Low-molecular-weight heparin in percutaneous coronary intervention: Ready for prime time?

ACC Current Journal Review

Volumn 11, Issue 2, 2002, Pages 59-64

  Young, John J ^a   Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DALTEPARIN; DANAPAROID; FIBRINOGEN RECEPTOR; HEPARIN; LOVENOX PLUS; LOW MOLECULAR WEIGHT HEPARIN; NORMIFLOW; REVIPARIN; TICLOPIDINE; WARFARIN;

CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0036223992     PISSN: 10621458     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1062-1458(02)00519-6     Document Type: Review

References (0)